GlassScriptPhysician profile
Aftab M Khan
NPI 1003075516
$9,678.60
in general payments reported to CMS, 2019-2025
45 companies · $1,836 in 2025
The $1,836 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $994 · 2021: $1,416 · 2022: $1,130 · 2023: $1,206 · 2024: $2,493 · 2025: $1,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,534.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,077.15 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $866.37 | 2019-2025 | Trintellix, Hyqvia |
| Abbvie INC. | $839.83 | 2021-2025 | |
| Bausch Health US, LLC | $683.66 | 2019-2022 | |
| Alkermes, INC. | $644.94 | 2019-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $526.24 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $496.05 | 2020-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $428.02 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $404.89 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Ucb, INC. | $353.85 | 2024-2025 | Briviact, Nayzilam, Rystiggo |
| Lundbeck LLC | $316.03 | 2022-2025 | Vyepti, Rexulti |
| Sunovion Pharmaceuticals INC. | $314.07 | 2021-2022 | |
| Axsome Therapeutics, INC. | $269.33 | 2023-2025 | Auvelity |
| Sk Life Science, INC. | $265.02 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $232.24 | 2024-2025 | Ultomiris |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $206.88 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Neos Therapeutics, LP | $169.03 | 2023 | Adzenys Xr-Odt |
| Janssen Biotech, INC. | $160.36 | 2025 | Tremfya |
| Almatica Pharma LLC | $140.81 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $132.27 | 2024-2025 | Nuplazid |
| Eisai INC. | $125.10 | 2020-2025 | |
| Lilly USA, LLC | $103.63 | 2023-2025 | Amyvid, Kisunla, Emgality |
| Biogen, INC. | $97.73 | 2024-2025 | Leqembi |
| Harmony Biosciences LLC | $93.04 | 2021-2025 | |
| Argenx US, INC. | $85.97 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $78.53 | 2024-2025 | |
| Octapharma USA, INC. | $74.31 | 2024-2025 | Panzyga |
| Corium, LLC | $66.33 | 2023-2024 | Azstarys |
| Scilex Pharmaceuticals INC. | $61.36 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $58.35 | 2024 | Xeomin |
| Mallinckrodt Hospital Products INC. | $47.41 | 2024 | Acthar |
| Tanabe Pharma America, INC. | $29.83 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $29.19 | 2025 | Rejoyn |
| Shire North American Group INC | $24.86 | 2019 | |
| Averitas Pharma INC. | $23.31 | 2024 | Qutenza |
| Vanda Pharmaceuticals INC. | $21.03 | 2025 | Ponvory |
| Acorda Therapeutics, INC | $20.61 | 2024 | Inbrija |
| Indivior INC. | $18.31 | 2022 | |
| Tris Pharma INC | $17.35 | 2024 | Dyanavel Xr |
| Astrazeneca Pharmaceuticals LP | $16.52 | 2025 | Wainua |
| Kyowa Kirin, INC. | $15.81 | 2024 | Nourianz |
| Allergan, INC. | $14.88 | 2020 | |
| Supernus Pharmaceuticals, INC. | $14.64 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.46 | 2024 | Horizant |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aftab Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.